麗珠醫藥(01513.HK)為控股附屬公司麗珠單抗提供融資擔保
格隆匯6月4日丨麗珠醫藥(01513.HK)公佈,於2021年6月4日召開的第十屆董事會第二十次會議上,審議通過《關於公司為控股附屬公司麗珠單抗提供融資擔保的議案》。
為滿足控股附屬公司珠海市麗珠單抗生物技術有限公司(以下簡稱"麗珠單抗")的業務需要及研發需求,同意公司在取得健康元藥業集團股份有限公司(以下簡稱"健康元集團")出具的《反擔保承諾書》(主要內容為:承諾為公司在麗珠單抗擔保責任範圍內提供33.07%的連帶保證責任,保證期至公司的保證責任結束之日止)後,為麗珠單抗向中國工商銀行股份有限公司等銀行申請最高不超過人民幣共計23.5億元或等值外幣的授信融資提供連帶責任擔保。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.